Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gilead, J & J Working on HIV Pills

By Drug Discovery Trends Editor | June 28, 2011

NEW YORK (AP) – Gilead Sciences Inc. and a unit of Johnson & Johnson say they plan to work together to develop a pair of combination HIV pills.

The companies said they have agreed to collaborate on a pill that combines Johnson & Johnson’s HIV drug Prezista with Gilead’s drug candidate cobicistat, which is designed to make other anti-retroviral drugs more effective. They are negotiating a collaboration that would create a drug combining Prezista with Gilead’s HIV drug Emtriva, along with another Gilead drug candidate called GS 7340. GS 7340 is a version of Gilead’s older drug Viread.

The deal won’t be completed unless the companies come to an agreement on the second combination pill. The companies did not disclose financial terms of the potential partnership, which would be between Gilead and Tibotec Pharmaceuticals, a unit of Johnson & Johnson’s Ortho Biotech Inc.

Tibotec would be responsible for formulating the first pill as well as for manufacturing, regulatory matters, and sales worldwide, while Gilead would be responsible for development and sales of the second product. Gilead retains all rights to cobicistat as a standalone product and for use with other drugs.

Date: June 28, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE